BRPI0912388A2 - composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças - Google Patents
composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doençasInfo
- Publication number
- BRPI0912388A2 BRPI0912388A2 BRPI0912388A BRPI0912388A BRPI0912388A2 BR PI0912388 A2 BRPI0912388 A2 BR PI0912388A2 BR PI0912388 A BRPI0912388 A BR PI0912388A BR PI0912388 A BRPI0912388 A BR PI0912388A BR PI0912388 A2 BRPI0912388 A2 BR PI0912388A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prophylaxis
- diseases
- treatment
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12652908P | 2008-05-05 | 2008-05-05 | |
| US18830308P | 2008-08-07 | 2008-08-07 | |
| PCT/CA2009/000611 WO2009135299A1 (en) | 2008-05-05 | 2009-05-04 | 3, 4 - substituted piperidine derivatives as renin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0912388A2 true BRPI0912388A2 (pt) | 2017-09-26 |
Family
ID=41264366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0912388A BRPI0912388A2 (pt) | 2008-05-05 | 2009-05-04 | composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8889714B2 (https=) |
| EP (1) | EP2274295B1 (https=) |
| JP (3) | JP4790871B2 (https=) |
| KR (2) | KR101403311B1 (https=) |
| CN (1) | CN102015682B (https=) |
| AU (1) | AU2009243875B2 (https=) |
| BR (1) | BRPI0912388A2 (https=) |
| CA (1) | CA2722734C (https=) |
| CO (1) | CO6311081A2 (https=) |
| CR (1) | CR11809A (https=) |
| DO (1) | DOP2010000329A (https=) |
| EA (1) | EA020853B1 (https=) |
| ES (1) | ES2548134T3 (https=) |
| IL (1) | IL208467A (https=) |
| MA (1) | MA32296B1 (https=) |
| MX (1) | MX2010012067A (https=) |
| MY (1) | MY152042A (https=) |
| NI (1) | NI201000188A (https=) |
| NZ (1) | NZ589019A (https=) |
| PL (1) | PL2274295T3 (https=) |
| SG (1) | SG192543A1 (https=) |
| SV (1) | SV2010003723A (https=) |
| WO (1) | WO2009135299A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| EP2376473A4 (en) * | 2008-12-10 | 2012-05-02 | Merck Canada Inc | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS |
| TWI562977B (en) * | 2010-11-05 | 2016-12-21 | Bayer Ip Gmbh | Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| CN107602381B (zh) * | 2017-09-11 | 2021-03-16 | 陕西莱特光电材料股份有限公司 | 一种萘甲酸酯类衍生物及其制备方法 |
| CN108033876A (zh) * | 2017-12-20 | 2018-05-15 | 江汉大学 | 一种5-溴-2-氯苯甲醛的制备方法 |
| US12459934B2 (en) | 2018-11-28 | 2025-11-04 | Basf Se | Pesticidal compounds |
| WO2021219513A1 (en) | 2020-04-28 | 2021-11-04 | Basf Se | Pesticidal compounds |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| TR199800409T1 (xx) | 1995-09-07 | 1998-05-21 | F.Hoffmann-La Roche Ag | Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler |
| US5994294A (en) | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| WO1998019672A1 (en) | 1996-11-01 | 1998-05-14 | Nitromed Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292426B1 (it) | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| CA2483241C (en) | 2002-04-29 | 2011-05-31 | Actelion Pharmaceuticals Ltd | Novel diazabicyclononene derivatives |
| RU2005102002A (ru) | 2002-06-27 | 2005-09-20 | Актелион Фармасьютиклз Лтд. (Ch) | Новые производные тетрагидропиридина |
| US20040204455A1 (en) | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
| CN1780836A (zh) | 2003-04-28 | 2006-05-31 | 埃科特莱茵药品有限公司 | 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物 |
| JP2007523845A (ja) | 2003-04-29 | 2007-08-23 | アクテリオン ファマシューティカルズ リミテッド | 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体 |
| KR20060008937A (ko) | 2003-04-30 | 2006-01-27 | 액테리온 파마슈티칼 리미티드 | 레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체 |
| KR20060006069A (ko) | 2003-04-30 | 2006-01-18 | 액테리온 파마슈티칼 리미티드 | 아자비사이클로노넨 유도체 |
| JP2006524657A (ja) | 2003-04-30 | 2006-11-02 | アクテリオン ファマシューティカルズ リミテッド | 新規トロパン誘導体 |
| EP1622564A2 (en) | 2003-05-02 | 2006-02-08 | Actelion Pharmaceuticals Ltd. | Diazabicyclononene derivatives |
| TW200900399A (en) | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
| CA2540543A1 (en) | 2003-10-09 | 2005-05-06 | Actelion Pharmaceuticals Ltd | Tetrahydropyridine derivatives |
| WO2005040165A1 (en) | 2003-10-13 | 2005-05-06 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| CA2540817A1 (en) | 2003-10-23 | 2005-05-06 | Olivier Bezencon | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
| AU2004295092A1 (en) | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd. | Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain |
| AU2004295091A1 (en) | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| AR053406A1 (es) | 2004-07-09 | 2007-05-09 | Speedel Experimenta Ag | Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas |
| WO2006021399A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Azabicyclononene derivatives as renin inhibitors |
| WO2006021401A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicylononene derivatives |
| ATE462703T1 (de) | 2004-08-25 | 2010-04-15 | Actelion Pharmaceuticals Ltd | Bicyclononen-derivate als renin-inhibitoren |
| WO2006021403A1 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicyclononene derivatives |
| WO2006058546A1 (en) | 2004-12-01 | 2006-06-08 | Actelion Pharmaceuticals Ltd | Novel lactame derivatives as renin inhibitors |
| AR052263A1 (es) | 2004-12-08 | 2007-03-07 | Actelion Pharmaceuticals Ltd | Derivado de diazabiciclononeno |
| WO2006063610A1 (en) | 2004-12-17 | 2006-06-22 | Actelion Pharmaceuticals Ltd | Heteroaryl substituted diazabicyclononene derivatives |
| GB0428526D0 (en) * | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| KR100938364B1 (ko) | 2005-01-28 | 2010-01-22 | 액테리온 파마슈티칼 리미티드 | 고혈압 치료를 위한, 레닌의 억제제로서의 7-｛4-[2-(2,6-디클로로-4-메틸페녹시)에톡시]페닐｝-3,9-디아자비시클로[3.3.1]논-6-엔-6-카르복실산 시클로프로필-(2,3-디메틸벤질)아미드 |
| WO2006092268A1 (en) | 2005-03-02 | 2006-09-08 | Actelion Pharmaceuticals Ltd | Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors |
| GB0504850D0 (en) | 2005-03-09 | 2005-04-13 | Novartis Ag | Organic compounds |
| BRPI0609534A2 (pt) | 2005-03-31 | 2010-04-13 | Speedel Experimenta Ag | piperidinas 3,4,5-substituìdas |
| TW200716622A (en) | 2005-03-31 | 2007-05-01 | Speedel Experimenta Ag | Substituted piperidines |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GEP20115206B (en) * | 2005-05-27 | 2011-04-26 | Actelion Pharmaceuticals Ltd | Novel piperidine carboxylic acid amide derivatives |
| GB0511063D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| WO2006131884A2 (en) | 2005-06-07 | 2006-12-14 | Actelion Pharmaceuticals Ltd | Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors |
| JP2009502751A (ja) | 2005-07-22 | 2009-01-29 | メルク フロスト カナダ リミテツド | レニン阻害薬 |
| WO2007034406A1 (en) | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
| WO2007034445A2 (en) | 2005-09-26 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency |
| WO2007049224A1 (en) | 2005-10-25 | 2007-05-03 | Actelion Pharmaceuticals Ltd | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives |
| BRPI0620736A2 (pt) | 2005-12-30 | 2011-12-20 | Novartis Ag | compostos orgánicos |
| EP1816122A3 (en) | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
| NZ570828A (en) | 2006-02-02 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Secondary amines as renin inhibitors |
| EP2029542A2 (en) | 2006-03-03 | 2009-03-04 | Actelion Pharmaceuticals Ltd. | Primary amines as renin inhibitors |
| CN101395149A (zh) | 2006-03-08 | 2009-03-25 | 埃科特莱茵药品有限公司 | 新颖胺类 |
| US20090318501A1 (en) | 2006-09-18 | 2009-12-24 | Baldwin John J | Piperidine derivatives as renin inhibitors |
| CA2668742A1 (en) * | 2006-11-17 | 2008-05-22 | Merck Frosst Canada Ltd. | Renin inhibitors |
| AU2008253519A1 (en) * | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd | Novel case of renin inhibitors |
| JP2010535716A (ja) | 2007-08-07 | 2010-11-25 | メルク フロスト カナダ リミテツド | レニン阻害剤 |
| US20100249163A1 (en) * | 2007-12-04 | 2010-09-30 | Daniel Dube | Renin inhibitors |
| JP2011520924A (ja) | 2008-05-22 | 2011-07-21 | メルク フロスト カナダ リミテツド | レニン阻害剤としての３，４−置換ピペリジン誘導体 |
| US20120190701A1 (en) | 2009-08-18 | 2012-07-26 | Merck Sharp & Dohme Corp. | Renin inhibitors |
-
2009
- 2009-05-04 KR KR1020107024856A patent/KR101403311B1/ko not_active Expired - Fee Related
- 2009-05-04 CN CN200980116219.5A patent/CN102015682B/zh not_active Expired - Fee Related
- 2009-05-04 JP JP2011507765A patent/JP4790871B2/ja not_active Expired - Fee Related
- 2009-05-04 SG SG2013055702A patent/SG192543A1/en unknown
- 2009-05-04 ES ES09741617.6T patent/ES2548134T3/es active Active
- 2009-05-04 CA CA2722734A patent/CA2722734C/en not_active Expired - Fee Related
- 2009-05-04 NZ NZ589019A patent/NZ589019A/xx not_active IP Right Cessation
- 2009-05-04 WO PCT/CA2009/000611 patent/WO2009135299A1/en not_active Ceased
- 2009-05-04 EP EP09741617.6A patent/EP2274295B1/en active Active
- 2009-05-04 EA EA201071269A patent/EA020853B1/ru not_active IP Right Cessation
- 2009-05-04 MX MX2010012067A patent/MX2010012067A/es active IP Right Grant
- 2009-05-04 KR KR1020137003332A patent/KR20130029116A/ko not_active Withdrawn
- 2009-05-04 US US12/990,927 patent/US8889714B2/en not_active Expired - Fee Related
- 2009-05-04 PL PL09741617T patent/PL2274295T3/pl unknown
- 2009-05-04 MY MYPI20105036 patent/MY152042A/en unknown
- 2009-05-04 BR BRPI0912388A patent/BRPI0912388A2/pt not_active Application Discontinuation
- 2009-05-04 AU AU2009243875A patent/AU2009243875B2/en not_active Ceased
-
2010
- 2010-10-04 IL IL208467A patent/IL208467A/en not_active IP Right Cessation
- 2010-11-03 DO DO2010000329A patent/DOP2010000329A/es unknown
- 2010-11-04 SV SV2010003723A patent/SV2010003723A/es not_active Application Discontinuation
- 2010-11-05 NI NI201000188A patent/NI201000188A/es unknown
- 2010-11-11 CO CO10141827A patent/CO6311081A2/es not_active Application Discontinuation
- 2010-11-11 MA MA33335A patent/MA32296B1/fr unknown
- 2010-11-24 CR CR11809A patent/CR11809A/es not_active Application Discontinuation
-
2011
- 2011-06-01 JP JP2011123057A patent/JP5653842B2/ja not_active Expired - Fee Related
- 2011-06-01 JP JP2011123054A patent/JP5587246B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0912388A2 (pt) | composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças | |
| BRPI0915084A2 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer | |
| BRPI0906786A2 (pt) | Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit. | |
| BRPI0814163A2 (pt) | Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI1009022A2 (pt) | "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" | |
| BR112013013435A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto. | |
| BRPI0821299A2 (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição. | |
| BRPI0914927A2 (pt) | composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
| BR122020011920A2 (pt) | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
| BRPI0715531A2 (pt) | Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto | |
| BRPI0718587A2 (pt) | Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo | |
| BRPI0906805A2 (pt) | Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
| BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia | |
| BRPI0811275A2 (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK CANADA INC. (CA) Owner name: MERCK SHARP AND DOHME LIMITED (GB) , MERCK CANADA |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE N?O FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |